CNV-2197944

DB15229InvestigationalSmall molecule

CNV-2197944 is under investigation in clinical trial NCT01893125 (Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy).

Mechanism: Pharmacologically active on Voltage-dependent N-type calcium channel subunit alpha-1B
Curator reviewed
Formula / weight: C₁₉H₂₀F₃N₃O₃S · 427.44 g/mol (avg)
Code names: CNV-2197944

Resolves to

Compound

UNIISSB9S6N20RCAS1204535-44-3

Structure

InChIKeyBLFJGFDZMABYMY-ZDUSSCGKSA-NSMILESC[C@H]1CN(CCN1C(=O)C1=CC=CN=C1C)S(=O)(=O)C1=CC=C(C=C1)C(F)(F)F

Targets

Q00975CACNA1B

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with CNV-2197944, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account